Bailard’s Actinium Pharmaceuticals ATNM Stock Holding History

Bailard’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-57,867	Closed	-$78.7K	–	749
2025 Q4	$78.7K	Buy	+57,867	New	+$84.4K	﹤0.01%	739

Other funds holding ATNM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bailard's ATNM Position: Q1 2026 in Review

Bailard sold out of Actinium Pharmaceuticals (ATNM) in Q1 2026, closing a stake of 57,867 shares — an estimated $78.7K sold.

Bailard first reported a position in ATNM in Q4 2025 and held it in 1 quarter. The position peaked at $78.7K in Q4 2025. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

Bailard reported no remaining Actinium Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Bailard sold 57,867 Actinium Pharmaceuticals shares in Q1 2026, an estimated $78.7K.
Bailard first reported a position in Actinium Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Bailard's Actinium Pharmaceuticals position peaked at $78.7K in Q4 2025.
54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Bailard's 13F filing for Q1 2026, filed 11 May 2026.